title: [Nephroprotection in young type 1 diabetic patients treated with converting enzyme inhibitor].
abstract: BACKGROUND
  Diabetic nephritis is a renal microangiopathy that represents a major cause of morbidity and mortality in diabetic patients. It is expressed either by microalbunuria, proteinuria or renal failure, depending on the stage of the diabetes. In this context, angiotensin converting enzyme inhibitors (ACEI) slow down the progression of renal damage.
  
  
  OBJECTIVE
  To assess the nephroprotector effects of ACEI in young type 1 Moroccan diabetics with varying stages of renal damage. Methods Prospective study including 29 patients exhibiting a diabetic nephropathy and/or hypertension having been followed-up for 1 year and treated with ACEI. The following parameters were analysed on inclusion, at six months and after 1 year of treatment: systolic arterial pressure (SAP), diastolic arterial pressure (DAP), mean arterial pressure (MAP), urinary excretion of albumin, 24-hour proteinuria, creatininemia, creatinine clearance, glycosylated haemoglobin, kalemia, total cholesterol and triglycerides.
  
  
  RESULTS
  The mean age of our patients was of 23.6 +/- 5.5 years, the age at onset of diabetes was of 9.3 +/- 2.6 years. According to the renal damage, we determined 4 groups of patients: Group I: microalbuminuria (10 patients), Group II: proteinuria (7 patients), Group III: renal failure (6 patients), Group IV: isolated hypertension (6 patients). Study of the progression of the clinical and biological parameters, during treatment with converting enzyme inhibitors (combined with diuretics in Groups II and III) revealed: In Group I: a decrease in urinary excretion of albumin, which returned to normal in 3 cases, in Group II: a decrease in the proteinuria, which became a microalbuminuria in 4 cases, in Group III: a stabilisation of renal function concomitant to a reduction in proteinuria, in Group IV: a significant reduction in mean arterial pressure.
  
  
  CONCLUSIONS
  One year of treatment with ACEI appears effective on reducing proteinuria levels and stabilising the renal function in young type 1 diabetic patients.
authors.affiliation: Service de néphrologie-hémodialyse, CHU Ibn Sina, Rabat, Maroc.
authors.forename: L
authors.initials: L
authors.lastname: Benamar
authors.forename: A
authors.initials: A
authors.lastname: Laboudi
authors.forename: H
authors.initials: H
authors.lastname: Rhou
authors.forename: I
authors.initials: I
authors.lastname: Laouad
authors.forename: Z
authors.initials: Z
authors.lastname: Fahi
authors.forename: Y
authors.initials: Y
authors.lastname: Bentata
authors.forename: Y
authors.initials: Y
authors.lastname: Amar
authors.forename: F
authors.initials: F
authors.lastname: Ezzaïtouni
authors.forename: N
authors.initials: N
authors.lastname: Ouzeddoun
authors.forename: R
authors.initials: R
authors.lastname: Bayahia
authors.forename: L
authors.initials: L
authors.lastname: Balafrej
authors.forename: A
authors.initials: A
authors.lastname: Touzani
authors.forename: B
authors.initials: B
authors.lastname: Benhamou
authors.forename: A
authors.initials: A
authors.lastname: Balafrej
authors.forename: A
authors.initials: A
authors.lastname: Guedira
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D003922:Diabetes Mellitus, Type 1 / Q000150:complications*; D003928:Diabetic Nephropathies / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control*; D018450:Disease Progression; D005260:Female; D006801:Humans; D008297:Male; D011446:Prospective Studies; D011507:Proteinuria / Q000209:etiology / Q000517:prevention & control
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors
vernacular_title: Néphroprotection chez le jeune diabétique de type 1 traité par inhibiteur d'enzyme de conversion. Résultats préliminaires d'une étude prospective.